Search company, investor...
Qualisure company logo


Founded Year



Incubator/Accelerator - II | Alive

About Qualisure

Qualisure develops genomics-based precision diagnostic products. The product helps oncologists to offer personalized cancer care treatments for every patient. It was founded in 2017 and is based in Calgary, Canada.

Headquarters Location

3553 36 Street North West Suite 762

Calgary, Alberta, T2L 1Y8,


(877) 764-7628

Qualisure's Product Videos

Compete with Qualisure?

Ensure that your company and products are accurately represented on our platform.

Qualisure's Products & Differentiators

    Thyroid GuidePx

    The first genomics-based prognostic test for papillary thyroid cancer.

Qualisure Patents

Qualisure has filed 1 patent.

patents chart

Application Date

Grant Date


Related Topics



Transcription factors, Proteins, Human proteins, Thyroid disease, Human genes


Application Date


Grant Date


Related Topics

Transcription factors, Proteins, Human proteins, Thyroid disease, Human genes



Qualisure Frequently Asked Questions (FAQ)

  • When was Qualisure founded?

    Qualisure was founded in 2017.

  • Where is Qualisure's headquarters?

    Qualisure's headquarters is located at 3553 36 Street North West, Calgary.

  • What is Qualisure's latest funding round?

    Qualisure's latest funding round is Incubator/Accelerator - II.

  • Who are the investors of Qualisure?

    Investors of Qualisure include Plug and Play Alberta and Canadian Technology Accelerator.

  • Who are Qualisure's competitors?

    Competitors of Qualisure include Agendia and 2 more.

  • What products does Qualisure offer?

    Qualisure's products include Thyroid GuidePx and 3 more.

Compare Qualisure to Competitors

Auspex Diagnostics

Auspex Diagnostics ceased operations. It provides artificial intelligence (AI) based advanced cancer diagnostics services intended to improve the quality of cancer care. The company's machine learning (ML) algorithm analyzes the genomic information of a patient's tumor sample and accurately assesses the risk of recurrence and drug efficacy, enabling the oncologists and patients to make the optimal data-driven decisions and personalize the treatment plan. It was founded in 2012 and is based in Warren, New Jersey.


OncoGenomX provides a predictive clinical decision support tool. It offers PredictionStar which is a patented algorithm for the analysis of tumor-specific genomic, biological, pathological, and patient-specific clinical information complemented by intelligence-augmented drug tumor matching, and calibration with real-world outcome data to guide evidence-based therapy decisions. It was founded in 2020 and is based in Allschwil, Switzerland.


Ataraxis develops an artificial intelligence (AI)-based diagnostic platform that helps doctors select the most optimal treatment for all patients. It was founded in 2022 and is based in New York City, New York.

Digistain Logo

Digistain applies machine learning algorithms to facilitate the provision of personalized risk reports to breast cancer patients and their physicians, helping reduce the timing and cost of treatment decisions, such as the need for chemotherapy. The platform technology uses infrared light to detect chemical changes occurring in tumor samples which can accompany the progression of the breast cancer disease. The company was founded in 2020 and is based in London, England.

Diagnostic Technologies

Diagnostic Technologies Ltd. (DTL) is a medical diagnostic and biotechnology company at the forefront of placental protein molecular biology and biochemistry. The company aims to become a major player in managing high risk pregnancies by commercialising a technology platform of versatile biotechnology products for detecting and managing at risk mothers for intrauterine growth restriction, preeclampsia and pre-term delivery. The company focuses on the development of diagnostic tools to aid in the assessment of high-risk pregnancies. In particular, the technology platform focuses on pregnancy related proteomics and genomics to produce specific and sensitive testing kits for the detection of high risk and problem pregnancies.

Stratipath Logo

Stratipath focuses on individualized medicine through AI-based precision diagnostics for cancer.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.